Table of Contents Author Guidelines Submit a Manuscript
Case Reports in Rheumatology
Volume 2013, Article ID 795027, 4 pages
Case Report

A Case of Hyperimmunoglobulinemia D Syndrome Successfully Treated with Canakinumab

1Pediatric Rheumatology Unit, 1st Department of Pediatrics, Children's Hospital “Aghia Sophia”, University of Athens, 115 27 Athens, Greece
2Department of Immunology & Histocompatibility, School of Medicine, University of Thessaly, 411 10 Biopolis, Larissa, Greece

Received 27 February 2013; Accepted 26 March 2013

Academic Editors: G. S. Alarcon, D. R. Alpert, A. Chalmers, and C. Saadeh

Copyright © 2013 Elena Tsitsami et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Citations to this Article [6 citations]

The following is the list of published articles that have cited the current article.

  • Jos W. M. van der Meer, “Treating inflammation by blocking interleukin-1 in humans,” Seminars in Immunology, vol. 25, no. 6, pp. 469–484, 2013. View at Publisher · View at Google Scholar
  • G. Dueckers, O. Sander, and T. Niehues, “Autoinflammatory Diseases (AID),” Klinische Padiatrie, vol. 226, no. 3, pp. 133–142, 2014. View at Publisher · View at Google Scholar
  • Adriana A. Jesus, and Raphaela Goldbach-Mansky, “ IL-1 Blockade in Autoinflammatory Syndromes 1 ,” Annual Review of Medicine, vol. 65, no. 1, pp. 223–244, 2014. View at Publisher · View at Google Scholar
  • C. M. Mulders-Manders, and A. Simon, “Hyper-IgD syndrome/mevalonate kinase deficiency: what is new?,” Seminars In Immunopathology, vol. 37, no. 4, pp. 371–376, 2015. View at Publisher · View at Google Scholar
  • Masoud Golpour, and Javad Ghaffari, “Hyperimmunoglobulin-D Syndrome in Children: A Review Article,” Journal of Pediatrics Review, vol. 4, no. 1, 2016. View at Publisher · View at Google Scholar
  • Gabriele Fenini, Emmanuel Contassot, and Lars E. French, “Potential of IL-1, IL-18 and Inflammasome Inhibition for the Treatment of Inflammatory Skin Diseases,” Frontiers in Pharmacology, vol. 8, 2017. View at Publisher · View at Google Scholar